News | VIVA | October 05, 2020

The Latest Vascular Interventional Clinical Data Presented at VIVA 2020

Top 10 trials listed below will be presented live

The Latest Vascular Interventional Clinical Data Presented at VIVA 2020 late-breaking sessions

October 5, 2020 — The Vascular Interventional Advances (VIVA) virtual conference will feature 10 late-breaking clinical trials sessions during the virtual meeting Nov. 6-7, 2020. A multidisciplinary, international panel of expert physicians, scientists and regulators will ask questions and shed light on the lasting impact of the research results as they are presented for the first time. 

For more information: https://vivaphysicians.org/clinical-trials

Friday, Nov. 6, 
Session beginning at 11 a.m. PT

   • 5-Year Outcomes from the IN.PACT Global Study. Presented by Thomas Zeller, M.D., Ph.D.

   • Drug-Coated Devices & Limb Outcomes After Endovascular Peripheral Artery Revascularizations. Presented by Connie N. Hess, M.D., MHS.

   • Standard vs Ultrasound-Assisted Thrombolysis for Submassive Pulmonary Embolism. Presented by Efthymios Avgerinos, M.D., Ph.D., MSc.

   • VIVO Study 12-Month Endpoint Results. Presented by Anthony Comerota, M.D.

   • PROMISE I 1-Year Results. Presented by Daniel Clair, M.D.

Saturday, Nov. 7 
Session beginning at 7 a.m. PT

   • DISRUPT PAD III RCT Acute Results: IVL vs PTA in Severe Calcium. Presented by William A. Gray, M.D.

   • REALITY Study: Directional Atherectomy Vessel Preparation Prior to DCB Angioplasty. Presented by Krishna Rocha-Singh, M.D.

   • 24-Month Outcomes from the DETOUR 1 Trial for Percutaneous Femoropopliteal Bypass. Presented by Ehrin Armstrong, M.D.

   • 2-Year Outcomes of a Multi-Centre Study on Infrapopliteal Bioresorbable Vascular Scaffold. Presented by Steven Kum, M.D.

   • 4-Year DCB Mortality Across ILLUMENATE RCTs. Presented by Sean Lyden, M.D.

 

Related VIVA Conference Content:

VIVA 2019 Late-breaking Clinical Trials

Other VIVA news


Related Content

News | Cardiovascular Clinical Studies

May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

Home May 02, 2024
Home
News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
Subscribe Now